Armocida Giuseppe, Licata Marta, Gorini Ilaria, Ciliberti Rosagemma
Centre of Research in Osteoarchaeology and Paleopathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Centre of Research in Osteoarchaeology and Paleopathology, Department of Biotechnology and Life Sciences, University of Insubria, O. Rossi, 9, 21100 Varese, Italy. E-mail:
Acta Med Hist Adriat. 2019 Jul 1;17(1):91-102. doi: 10.31952/amha.17.1.5.
In the first half of the 20th century, in most European countries, it was thought that cholinesterase and other drugs that counteract acetylcholine should reduce the manifestations of schizophrenia. In 1937, Fiamberti (1894-1970) introduced the transorbital method of lobotomy which established the use of acetylcholine shock treatment for curing the disturbances of schizophrenia. Accepting the idea that the psychic alterations of schizophrenia were caused by a pathological interruption of nerve conduction at a presumably cortical level, Fiamberti thought he could apply this to the clinical field using the properties of acetylcholine, an acetic ester of choline. Here, we examined, in detail, the contribution of Mario Fiamberti to acetylcholine therapy.
在20世纪上半叶,大多数欧洲国家认为胆碱酯酶和其他对抗乙酰胆碱的药物应能减轻精神分裂症的症状。1937年,菲亚姆贝蒂(1894 - 1970)引入了经眶叶切断术,开创了使用乙酰胆碱休克疗法来治疗精神分裂症障碍。菲亚姆贝蒂接受了这样一种观点,即精神分裂症的精神改变是由假定在皮质水平的神经传导病理性中断所致,他认为可以利用胆碱的乙酸酯——乙酰胆碱的特性将其应用于临床领域。在此,我们详细考察了马里奥·菲亚姆贝蒂对乙酰胆碱疗法的贡献。